Topotecan 0.25 MG Oral Capsule — RxCUI 747195
RxNorm drug concept · Semantic clinical drug
RxCUI 747195
Semantic clinical drug · SCD
● Current RxNorm concept 2 FDA products
2 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI747195
Official nameTopotecan 0.25 MG Oral Capsule
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known astopotecan 250 MCG Oral Capsule; topotecan HCl 0.25 MG Oral Capsule
FDA products mapped2
Package NDCs mapped2
Reported Medicaid activity (SDUD)12 prescriptions · 1 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Topotecan: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Topotecan is a chemotherapy used for three types of cancer: small cell lung cancer (SCLC), metastatic ovarian cancer, and advanced cervical cancer. The IV form covers all three, de...
- What exactly is topotecan used to treat?
- The most common effects are drops in blood counts — low white blood cells, red blood cells, and platelets — along with nausea, vomiting, hair loss, fatigue, and bowel changes. Most...
- What side effects should I expect, and which ones should make me call someone right away?
🕸️ Concept Web — How Topotecan 0.25 MG Oral Capsule Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Topotecan 0.25 MG Oral Capsule
RxCUI 747195 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Topotecan
57308IN
-
Topotecan
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Hycamtin
203472BN
-
Hycamtin
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Topotecan Oral Capsule
747192SCDF -
Topotecan Oral Product
1157656SCDG -
Topotecan Pill
1157657SCDG -
Topotecan Oral Capsule [Hycamtin]
748737SBDF -
Hycamtin Oral Product
1172715SBDG -
Hycamtin Pill
1172716SBDG -
Oral Capsule
316965DF -
Oral Product
1151131DFG - +1 more in this family
-
Topotecan Oral Capsule
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Topotecan 0.25 MG
747194SCDC -
Topotecan 0.25 MG Oral Capsule [Hycamtin]
748738SBD -
Topotecan 0.25 MG [Hycamtin]
748736SBDC
-
Topotecan 0.25 MG
Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Topotecan 0.25 MG
SCDC · 747194 -
Topotecan Oral Capsule
SCDF · 747192 -
Topotecan Oral Product
SCDG · 1157656 -
Topotecan Pill
SCDG · 1157657
Brand-Name Concepts
-
Topotecan 0.25 MG Oral Capsule [Hycamtin]
SBD · 748738 -
Topotecan 0.25 MG [Hycamtin]
SBDC · 748736 -
Topotecan Oral Capsule [Hycamtin]
SBDF · 748737 -
Hycamtin Oral Product
SBDG · 1172715 -
Hycamtin Pill
SBDG · 1172716 -
Hycamtin
BN · 203472
📦 FDA Products & Package NDCs
2 products · 2 package NDCs
2 package NDCs map to RxCUI 747195 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 66758-0101-11 | 10 CAPSULE in 1 BOTTLE (66758-101-11) | HYCAMTIN | Sandoz Inc | 2025-01-06 |
| 66758-0102-11 | 10 CAPSULE in 1 BOTTLE (66758-102-11) | HYCAMTIN | Sandoz Inc | 2024-11-01 |
Observed labelers:
Sandoz Inc (2)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🧾 Billing Codes (HCPCS)
Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.
| Code | Descriptor | Mapped packages | Sources |
|---|---|---|---|
| J8705 | Topotecan oral | 2 | CMS |
⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.